I hesitated while pasting together this Bio-Twitter Year in Review because... Does anyone really want to remember what happened in 2016?

Don't all raise your hands at once; 2016 was a lousy year for biotech investors. It started bad, got worse, perked up, got worse again, rebounded just a little, looked like it was normalizing then tanked -- again.


Still, if we have to look back at the pain, why not have some fun with it? I combed through my Twitter archive to compile a 2016 biotech review in tweets. Month by month, here's how 2016 went -- for you  and for me. 


You know a bad year is coming when your beloved dog dies right after New Year's Day. 

Max died today. We're heartbroken. Lover of tennis balls, water, mud & runs in woods. My best buddy. I miss him. ❤️ pic.twitter.com/o0wRekNdIe

— Adam Feuerstein (@adamfeuerstein) January 4, 2016

MannKind (MNKD - Get Report) kaboom!

And on the second business day of 2016…$SNY ditches $MNKD

— Adam Feuerstein (@adamfeuerstein) January 5, 2016

Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference.

When you wake up at 3 am excited for lots of big, surprising #JPM16 Monday biotech news but instead get… pic.twitter.com/THDd05lgs8

— Adam Feuerstein (@adamfeuerstein) January 11, 2016

This! (Followed fast by the FDA's decision to postpone the Sarepta (SRPT - Get Report) advisory panel.)

$SRPT — eteplirsen dystrophin production better than drisapersen but not saying much. 0.9% of normal. Yikes.

— Adam Feuerstein (@adamfeuerstein) January 15, 2016

Biotech stocks cratered...

@bradloncar pic.twitter.com/jv0QCQ5HTx

— Adam Feuerstein (@adamfeuerstein) January 22, 2016

By the end of January, there was nowhere for investors to hide...

. @bradloncar Sorta like this, Brad. pic.twitter.com/Ko36AJFIoP

— Adam Feuerstein (@adamfeuerstein) January 29, 2016


No, dumbass, four more years of Trump! 

Can someone please remind me. If Punxsutawney Phil sees his shadow tomorrow, does that mean six more weeks of Trump?

— Adam Feuerstein (@adamfeuerstein) February 1, 2016

And surely someone shouted, "Buy the Gilead (GILD - Get Report) dip!" 

$GILD 2016 net product sales guidance $30-31B versus actual 2015 net product sales $32.2B

— Adam Feuerstein (@adamfeuerstein) February 2, 2016

The only good news I had in 2016.

When your daughter receives a letter saying she was accepted to college. pic.twitter.com/uXKeOG6ViK

— Adam Feuerstein (@adamfeuerstein) February 18, 2016

Brief tenure?

Dr. Robert Califf, the new FDA commissioner.

— Adam Feuerstein (@adamfeuerstein) February 24, 2016

We were so hopeful, but we're still waiting... 

Yeezus on $GILD M&A coming out of his conference y'day: pic.twitter.com/m7M1xmT2Ax

— Adam Feuerstein (@adamfeuerstein) February 25, 2016

Taking out the trash.

This list... Updated

1. $HEB fires Bill Carter
2. $GALE lawsuit settlement
3. $CTIC NDA withdrawal
4. $CPRX $PTCT RTF letters
5. $PPHM fail

— Adam Feuerstein (@adamfeuerstein) February 25, 2016


Al Mann, 90, is dead. $MNKD was an anomaly in a hugely successful career as businessman, generous philanthropist. Peace to his family.

— Adam Feuerstein (@adamfeuerstein) February 26, 2016

My new best friend.

Big news! Meet new member of my family. Just adopted. We'll be picking up this cutie this wknd or next. Dog ❤️!! pic.twitter.com/2FRwUSh2wP

— Adam Feuerstein (@adamfeuerstein) February 29, 2016


Celldex (CLDX - Get Report) blew up, one of many this year. 

$CLDX Rintega "ACT IV" ph3 brain tumor study stopped for futility at interim analysis. I had hope for this one, but not to be. Fail.

— Adam Feuerstein (@adamfeuerstein) March 7, 2016

Valeant (VRX) was a dumpster fire.

pearson out $VRX

— zach (@zbiotech) March 21, 2016


Yes,  Q1 was bad.

It's over! "It" is the 4th-worst quarter for biotech stocks ever. Moving on... https://t.co/Vc9Wv67qxW

— Adam Feuerstein (@adamfeuerstein) April 1, 2016

That Pfizer (PFE - Get Report) Allergan (AGN - Get Report) merger wasn't to be.

I imagine @brentlsaunders and Ian Reed feel like this. $PFE $AGn pic.twitter.com/ZnksNZwxmN

— Adam Feuerstein (@adamfeuerstein) April 6, 2016

THE FDA adcomm of 2016.

View from inside $SRPT adcom ballroom... more than an hour before it begins pic.twitter.com/1TGZY3SkJx

— Meg Tirrell (@megtirrell) April 25, 2016

The outcome looked bleak, but... 

$SRPT — I know we focus mostly on stocks here but there should be no joy or gloating over the negative panel vote. This was really tough.

— Adam Feuerstein (@adamfeuerstein) April 25, 2016

There was this.... 

Top FDA officials, including Janet Woodcock, said some remarkably positive things about $SRPT at Monday's panel —> https://t.co/4m4kJUjxQh

— Adam Feuerstein (@adamfeuerstein) April 28, 2016


M&A in May! (Just not enough of it.)

$PFE buying $ANAC $5.2b

— Adam Feuerstein (@adamfeuerstein) May 16, 2016

The wait continued.

$SRPT Announces FDA Will Not Complete The Review Of The Eteplirsen NDA By The PDUFA Date

— Bio Stocks™ (@BioStocks) May 25, 2016


Anyone want to take back their choice?

Response to my big-cap biotech turnaround poll question. $GILD by wide margin. pic.twitter.com/wlOqZAs6pV

— Adam Feuerstein (@adamfeuerstein) June 7, 2016

The biotech circle of life.

Data. Dilution.
Data. Dilution.
Data. Dilution.
Data. Dilution.
Data. Dilution.

And on and on it goes. Biotech Summer 2016.

— Adam Feuerstein (@adamfeuerstein) June 20, 2016

The year started bad, and never really stopped being bad.

Been thinking about the mid-way point of the year in biotech stocks and life science. This just about sums it up. pic.twitter.com/ehRZsL8brX

— Adam Feuerstein (@adamfeuerstein) June 30, 2016


Uh oh...

$JUNO clinical hold JACAR015

— Brad Loncar (@bradloncar) July 7, 2016


$MNKD, at investor conference earlier this week, excited Afrezza NRx are "stabilizing."

Squint, you might see it. pic.twitter.com/nHsPTEEK7d

— Adam Feuerstein (@adamfeuerstein) July 15, 2016

Drug pricing was the issue that never went away in 2016.

$ARIA has taken another +9% price increase on Iclusig in July after +8% in April and +9% in Jan.

Price hike now once per quarter...

— Andy Biotech (@AndyBiotech) July 29, 2016


Bristol-Myers Squibb (BMY - Get Report) committed one of the biggest "oops!" of 2016. 

$BMY Opdivo 1st line lung cancer failure is a stunner. $MRK emerges big winner.

— Adam Feuerstein (@adamfeuerstein) August 5, 2016

And there were gifs...

And now, in gifs… $BMY pic.twitter.com/U5iDgV9i3r

— Adam Feuerstein (@adamfeuerstein) August 5, 2016

$MRK pic.twitter.com/RZQPvJQsNM

— Adam Feuerstein (@adamfeuerstein) August 5, 2016

It was a great ride. 

Tomorrow, I will wear this #PMC2016 jersey w/ pride and gratitude for your help raising $31K to fight cancer. Woot! pic.twitter.com/wA0eJAKNq0

— Adam Feuerstein (@adamfeuerstein) August 5, 2016

We were still waiting...

$SRPT Mid-August. Pondering these three graphs depicting eteplirsen scenarios. pic.twitter.com/vy4tGN7M76

— Adam Feuerstein (@adamfeuerstein) August 9, 2016

Medivation (MDVN) delivered.

$MDVN CEO David Hung has guaranteed his first-ballot entry into the Biotech Deal Maker Hall of Fame w/ $14B $PFE takeout.

— Adam Feuerstein (@adamfeuerstein) August 22, 2016



She's settled in her dorm. The goodbye was hard. You raise her, watch over her, love her with all your being and then you let her fly. ❤️❤️

— Adam Feuerstein (@adamfeuerstein) September 3, 2016


POLL: $SRPT -- Will FDA approve eteplirsen in this review cycle i.e. No more data needed?

— Adam Feuerstein (@adamfeuerstein) September 9, 2016

Finally! But the arguments and doubts followed fast. 

And there it is…. $SRPT eteplirsen approved.

FDA letter —> https://t.co/KoxupYjLIb

— Adam Feuerstein (@adamfeuerstein) September 19, 2016

We made fun of sell-side analysts a lot in 2016. Mostly, they deserved it. 

$PBYI — Credit Suisse DOUBLED its PT to $111 from $54. pic.twitter.com/wWmPeDMBDT

— Adam Feuerstein (@adamfeuerstein) September 22, 2016


$OPHT -10% on $REGN anti-PDGFR study fail.

— Adam Feuerstein (@adamfeuerstein) September 30, 2016


CTI Biopharma (CTIC - Get Report) CEO Jim Bianco resigns: W.O.A.T.

Dear Jim Bianco: pic.twitter.com/uIbMCWwaDy

— Adam Feuerstein (@adamfeuerstein) October 3, 2016

This chart tracks the stock performance of $CTIC since its IPO. pic.twitter.com/4tT7WloyLG

— Adam Feuerstein (@adamfeuerstein) October 3, 2016

Ariad Pharma (ARIA) does it wrong. 

$ARIA Iclusig price increase history , per SunTrust, (With my added comment.) pic.twitter.com/JbRsobycjo

— Adam Feuerstein (@adamfeuerstein) October 5, 2016

Alnylam (ALNY)  -- yet another biotech blowup in 2016.

Alnylam Pharmaceuticals Discontinues Revusiran Development $ALNY

— zach (@zbiotech) October 5, 2016



POLL! Please vote. Describe your healthcare investing mood right now, as Q3 earnings draw to close.

— Adam Feuerstein (@adamfeuerstein) November 1, 2016

We can praise the sell-side, too. 

Brian Skorney's $CEMP note is why I have total respect for him as a sell-side analyst. Tough job but not afraid to say, I was wrong. pic.twitter.com/BVJDuNq1rI

— Adam Feuerstein (@adamfeuerstein) November 2, 2016

Little did we know at that time, Alexion (ALXN - Get Report)

$ALXN 10-Q, where art thou?

— Adam Feuerstein (@adamfeuerstein) November 9, 2016

The brief Trump Bump.

$IBB closes up 8.93%, biggest gain since Oct 13 2008, which closed up 9.87%.
Same story for $XBI (closed up 10.37% vs 13.26% Oct 13 2008)

— Caroline Chen (@CarolineYLChen) November 9, 2016


$LLY — solanezumab fails primary cognitive endpoint in phase 3 clinical trial. —> https://t.co/5VLjkAWlKd

— Adam Feuerstein (@adamfeuerstein) November 23, 2016

And on the same day! 

$JUNO Places JCAR015 Phase II ROCKET Trial on Clinical Hold https://t.co/VhsMiBBuxC

— Odi (@odibro) November 23, 2016


But the beta-amyloid hypothesis lives on...

I just came out of seeing "Manchester by the Sea" (good movie) and see the BETA AMYLOID HYPOTHESIS LIVES ON. pic.twitter.com/nv39HutrBX

— Adam Feuerstein (@adamfeuerstein) December 9, 2016

Let's hope 2017 is better than 2016. It could hardly be worse. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.